Denali TherapeuticsDNLI
DNLI
About: Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Employees: 390
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
72% more call options, than puts
Call options by funds: $2.01M | Put options by funds: $1.17M
61% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 23
33% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 58
31% more capital invested
Capital invested by funds: $2.81B [Q2] → $3.68B (+$874M) [Q3]
7% more funds holding
Funds holding: 201 [Q2] → 215 (+14) [Q3]
3.51% more ownership
Funds ownership: 84.74% [Q2] → 88.25% (+3.51%) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$28
31%
upside
Avg. target
$50
133%
upside
High target
$90
320%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Stifel Paul Mattels 0% 1-year accuracy 0 / 1 met price target | 72%upside $37 | Buy Upgraded | 16 Dec 2024 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target | 320%upside $90 | Buy Reiterated | 7 Nov 2024 |
Jefferies Michael Yee 10% 1-year accuracy 1 / 10 met price target | 110%upside $45 | Buy Maintained | 1 Nov 2024 |
JP Morgan Jessica Fye 50% 1-year accuracy 20 / 40 met price target | 31%upside $28 | Overweight Maintained | 11 Oct 2024 |
Financial journalist opinion
Negative
Zacks Investment Research
1 week ago
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
Neutral
Zacks Investment Research
2 weeks ago
Denali Starts Dosing in Phase II Parkinson's Disease Study
DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.
Neutral
Seeking Alpha
1 month ago
Denali Has A Neurodegenerative Edge Despite Market Skepticism
Denali Therapeutics' unique blood-brain barrier technology and strategic partnerships offer a significant edge in the challenging neurodegenerative disease landscape. The company's strong cash position and disciplined financial strategy support its ambitious R&D and commercialization efforts without immediate need for additional funding. Denali's pipeline targets critical neurodegenerative pathways, with promising candidates for lysosomal storage disorders, Parkinson's disease, and neuroinflammation.
Negative
Zacks Investment Research
1 month ago
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
Neutral
GlobeNewsWire
1 month ago
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided business highlights.
Negative
Zacks Investment Research
1 month ago
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Denali Therapeutics (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
3 months ago
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
Denali Therapeutics (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Positive
Zacks Investment Research
3 months ago
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
Neutral
GlobeNewsWire
3 months ago
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the outcome of a recent successful meeting with the Center for Drug Evaluation and Research (CDER) division of the U.S. Food and Drug Administration (FDA) providing a path to filing a biologics license application (BLA) for accelerated approval and subsequent conversion to full approval for tividenofusp alfa (DNL310) for the treatment of MPS II (Hunter syndrome). Agreement was reached that cerebrospinal fluid heparan sulfate (CSF HS) is reasonably likely to predict clinical benefit and can be used as a surrogate endpoint to support accelerated approval for tividenofusp alfa in MPS II. Based on discussions with CDER, Denali will include preclinical and clinical data on biomarkers (CSF HS and neurofilament light (NfL)) and safety in the BLA for tividenofusp alfa as a treatment of MPS II and intends to submit the BLA under the accelerated approval pathway in early 2025.
Positive
Seeking Alpha
4 months ago
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company's $500 million capital raise supports its aggressive R&D investment, providing a runway for developing its pipeline.
Charts implemented using Lightweight Charts™